吉西他滨联合奥沙利铂、地塞米松治疗非霍奇金淋巴瘤疗效观察

目的：观察吉西他滨联合奥沙利铂、地塞米松（GLD）方案治疗非霍奇金淋巴瘤（NHL）的有效性和安全性。方法回顾分析2011年1月—2014年9月诊治的35例 NHL 患者，给予吉西他滨1000 mg·m －2，d1，8，静脉滴注；奥沙利铂130 mg· m －2静脉滴注 d1，地塞米松20 mg·d －1，d1～4，静滴，每3周重复，2个周期评价疗效，治疗期间进行不良反应评估。结果35例 NHL 患者中，完全缓解（CR）7例，部分缓解（PR）11例，维持稳定（SD）4例，进展（PD）13例，客观有效率（ORR）为51．4％，疾病控制率（DCR）为62．9％；22例患者可评价无疾病进展期（PFS），中位 PFS 为5个月（95％CI：0～17．7个月），中位总生存期（OS）为9．5个月（95％CI：7．8～34．2个月）；主要不良反应为骨髓抑制，胃肠道反应、肝肾功能损害和神经毒性。结论GLD 方案对 NHL 有一定疗效，不良反应可耐受，是一个值得进一步研究的化疗方案。

Observation of gemcitabine,oxaliplatin and dexamethasone combination treatment for non-Hodgkin lymphoma

Objective To observe the efficacy and toxicity of gemcitabine,oxaliplatin and dexamethasone(GLD)combination treatment for non-Hodgkin lymphoma.Methods Thirty-five patients with non-Hodgkin lymphoma received gemcitabine (1 000 mg·m -2 iv gtt) on day 1 ,8 and oxaliplatin (130 mg·m -2 iv gtt)on day 1,dexamethasone (20 mg·d -1 iv gtt)on day 1 ~4.One cycle was 21 days. Adverse reactions were assessed during treatment.Results In the 35 cases,7 patients achieved complete response(CR),11 patients partial response(PR),4 patients stable disease(SD),and 13 patients progress disease(PD).The objective response rate(ORR)and disease control rate(DCR)were 51.4%,62.9% respectively.PFS could be assessed in 22 patients.Median progression-free survival and median overall survival were 5 months (95%CI:0 ~17.7 months)and 9.5 months(95%CI:7.8 ~34.2 months),respectively. The common adverse reactions were myelosuppression,gastrointestinal tract reaction,hepatic and renal functional lesion and neurotoxici-ty.Conclusion Gemcitabine,oxaliplatin and dexamethasone combination treatment for non-Hodgkin lymphoma can achieve efficacy with tolerated adverse reactions.The chemotherapy regimen is worthy of further study.